Posted by Michael Wonder on 12 Oct 2019
FDA approves new treatment for patients with migraine
11 October 2019 - The U.S. FDA today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.
Reyvow is not indicated for the preventive treatment of migraine.
The effectiveness of Reyvow for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials.
